A total of 71.95 per cent of share capital were represented at the 47. Annual General Meeting of Shareholders (AGM) of Oerlikon via the authority that was granted by shareholders to the Independent Proxy, Proxy Voting Services GmbH. Shareholders did not attend the AGM in person in line with the ordinance from the Federal Council of Switzerland in the fight against the coronavirus. Following the instructions given to the Independent Proxy, all resolutions were approved by a large majority, including the maximum aggregate total compensation of the Board for their term of office (AGM 2020 to AGM 2021), the maximum aggregate fixed compensation of the Executive Committee (EC) for the period July 1, 2020 through June 30, 2021 and the retrospective variable compensation of the EC for 2019, as well as the dividend payout of CHF 1.00 per share for 2019.
Prof. Dr. Michael Süss was reelected as the Chairman of the Board of Directors. Mrs. Irina Matveeva was elected as a new member of the Board, while Paul Adams, Geoffery Merszei, Alexey V. Moskov, Gerhard Pegam and Dr. Suzanne Thoma were all reelected as members of the Board. Furthermore, shareholders approved the reelection of Prof. Dr. Michael Süss, Paul Adams, Alexey V. Moskov, Gerhard Pegam und Dr. Suzanne Thoma as members of the Human Resource Committee. All elected Board members will serve a one-year term.
Oerlikon engineers materials, equipment and surfaces and provides expert services to enable customers to have high-performance products and systems with extended lifespans. Drawing on its key technological competencies and strong financial foundation, the Group is sustaining mid-term growth by addressing attractive growth markets, securing structural growth and expanding through targeted mergers and acquisitions. A leading global technology and engineering Group, Oerlikon operates its business in two Segments – Surface Solutions and Manmade Fibers – and has a global footprint of more than 11 100 employees at 182 locations in 37 countries. In 2019, Oerlikon generated CHF 2.6 billion in sales and invested more than CHF 120 million in R&D.
